Evonile Pharma Limited (BOM:500672)
India · Delayed Price · Currency is INR 1,762.40
+48.05 (2.80%)
At close: Nov 6, 2026
Evonile Pharma Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 3,328 | 3,543 | 3,563 | 3,351 | 3,787 | 3,999 |
Revenue Growth | -6.20% | -0.55% | 6.33% | -11.53% | -5.28% | 4.86% |
Gross Profit Gross Profit Growth | 1,289 | 1,560 | 1,535 | 1,351 | 1,771 | 2,217 |
Operating Income Operating Income Growth | 395.9 | 944.1 | 895.2 | 629.2 | 600.8 | 237.7 |
Net Income Net Income Growth | -39.9 | 931.8 | 1,009 | 851.9 | 1,034 | -37.2 |
Earnings Per Share EPS Growth | -1.62 | 37.74 | 40.87 | 34.50 | 41.86 | -1.51 |
EPS Growth | - | -7.65% | 18.44% | -17.58% | - | - |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 3,026 | 6,575 | 6,371 | 5,850 | 5,544 | 5,163 |
Total Debt Total Debt Growth | 7,960 | 32.1 | 50.6 | 69.7 | 215.1 | 240.1 |
Net Cash (Debt) Net Cash Growth | -4,935 | 6,543 | 6,320 | 5,780 | 5,329 | 4,923 |
Net Cash Growth | - | 3.53% | 9.34% | 8.46% | 8.25% | 13.19% |
Net Cash Per Share Net Cash Per Share Growth | -199.84 | 265.00 | 255.97 | 234.10 | 215.83 | 199.38 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 1,729 | 467.3 | 745.7 | 1,134 | 448 | 386.7 |
Capital Expenditures CapEx Growth | -13,136 | -3.4 | - | - | -3.1 | -5 |
Free Cash Flow Free Cash Flow Growth | -11,406 | 463.9 | 745.7 | 1,134 | 444.9 | 381.7 |
Free Cash Flow Growth | - | -37.79% | -34.24% | 154.89% | 16.56% | - |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 38.75% | 44.02% | 43.07% | 40.32% | 46.75% | 55.44% |
Operating Margin | 11.90% | 26.65% | 25.13% | 18.78% | 15.86% | 5.94% |
Pretax Margin | 0.57% | 36.59% | 36.61% | 36.66% | 30.46% | -0.96% |
Profit Margin | -1.20% | 26.30% | 28.32% | 25.42% | 27.29% | -0.93% |
FCF Margin | -342.76% | 13.09% | 20.93% | 33.84% | 11.75% | 9.55% |
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 25.000 | 25.000 | 10.000 | 10.000 |
Dividend Per Share Growth | 0% | 150.00% | 0% | 0% |
Dividend Yield | 3.19% | 2.43% | 1.77% | 1.69% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 7, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | 25.72 | 19.21 | 29.81 | 13.50 | - |
P/FCF Ratio | - | 51.67 | 25.99 | 22.40 | 31.37 | 38.19 |
PS Ratio | 13.08 | 6.77 | 5.44 | 7.58 | 3.69 | 3.65 |